Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

Breast cancer incidence rates are rising in low and middle-income countries (LMIC), and
these populations have reduced access to advanced multidisciplinary treatment. Screening …

An update is available for this article. Description: This guideline updates the 2017 American
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …

PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …

PURPOSE To update recommendations of the American Society of Clinical Oncology
(ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in …

Unlike female breast cancer, male breast cancer (MBC) is rare and not very well understood.
Prospective data in the management of MBC are lacking and majority of treatment strategies …

Purpose Many patients with hormone receptor–positive (HR+) breast cancer do not adhere
to endocrine therapy (ET), and treatment-related side effects are often discussed by …

Male breast cancer (MaBC) is a rare clinical entity, which makes up approximately 1% of all
breast cancers. However, the incidence of MaBC has been steadily increasing over the past …

Background Breast cancer is rare in men and managed by extrapolating from breast cancer
in women. The clinicopathological features of male breast cancer, however, differ from those …

Simple Summary Male breast cancer is a rare disease, representing around 0.5% of the
malignances in men. Although they receive the same treatment as women with breast …